Navigating the world of cell and gene therapy development and commercialisation

By Annabel Kartal-Allen | Published: 27-Sep-2024
Cell & Gene Therapy

Manufacturing Chemist’s Annabel Kartal-Allen (AKA) spoke to Adam Goldstein (AG), Senior Director of R&D Collaborations at Thermo Fisher Scientific, about the current trends in CGT manufacturing and how to optimise and commercialise the process

You need to be a subscriber to read this article.
Click here to find out more.

Initially discussing the latest trends in the biopharma industry, Adam notes that process analytical technology (PAT) has seen significant evolution in recent years and become an important component in terms of accelerating development timelines. PAT solutions enable the simple scaling of manufacturing processes to facilitate the production of biologics and cell and gene therapies (CGTs).

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.

Subscribe now Already a subscriber? Sign in here.
  • Companies:
  • Thermo Fisher Scientific
See more

You may also like

Cell & Gene Therapy

Thermo Fisher Scientific opens East Coast ATxCC to accelerate cell and gene therapy development

Read more
Thermo Fisher has launched its new Philadelphia-based Advanced Therapies Collaboration Center, expanding support for emerging biotechs with integrated lab space, specialist expertise and access to cutting-edge CGT development technologies

Trending Articles

  1. Thermo Fisher Scientific opens East Coast ATxCC to accelerate cell and gene therapy development Thermo Fisher has launched its new Philadelphia-based Advanced Therapies Collaboration Center, expanding support for emerging biotechs with integrated lab space, specialist expertise and access to cutting-edge CGT development technologies
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    Standardisation, digital maturity and the path ahead in cell and gene therapy With the promise of more personalised and potentially curative treatments, regulatory agencies are forecasting a surge in cell and gene therapy (CGT) approvals, reports Dr Matthew Lakelin, Head of Consultancy Services at TrakCel
  3. GenEditBio and ToolGen strike cross-license deal to advance next-generation in vivo genome-editing therapies The agreement combines ToolGen’s CRISPR-Cas9 platform with GenEditBio’s LNP delivery technology to accelerate development of once-and-done genome-editing treatments
  4. Anti-IL-21 monoclonal antibody licensed by Almirall NN-8828, the IL-21 blocker, is exclusively owned by Almirall and will be used to treat immune inflammatory dermatological diseases
  5. Towards the enzymatic synthesis of oligonucleotides: part II By early 2020, ten oligonucleotide drugs had received US FDA regulatory approval; with many more in the pipeline, it’s only fair to say that this drug class is becoming big business

Upcoming event

Pharmapack

21–22 January 2026 | Exhibition | Paris, France See all

You may also like

Cell & Gene Therapy

Thermo Fisher Scientific opens East Coast ATxCC to accelerate cell and gene therapy development

Thermo Fisher has launched its new Philadelphia-based Advanced Therapies Collaboration Center, expanding support for emerging biotechs with integrated lab space, specialist expertise and access to cutting-edge CGT development technologies
Cell & Gene Therapy

Thermo Fisher launches next-gen microarray analyser to accelerate pharmacogenomic research

The analyser combines four key genotyping processes into a single, integrated device, allowing researchers to cover the widest range of populations for genome-wide association studies
Manufacturing

Thermo Fisher teams up with Xcellbio to further cell and gene therapy research

The pair will focus on Treg and TIL research, with the intention of developing therapeutics for autoimmune and solid tumour diseases
Manufacturing

Thermo Fisher Scientific enhances biologics manufacturing sustainability with biobased solutions

The single use, plant-based film for bioprocessing containers can reduce the carbon footprint of biologics manufacturing by eliminating the need for plastic resin
Manufacturing

Multiply Labs and Thermo Fisher Scientific expand partnership to automate cell expansion and separation

Automating GMP-ready instruments using robotic technology helps reduce costs and accelerates timelines
Finance

Funding for commercialisation of Rexgenero cell therapy

TrakCel, a specialist software developer for cell and gene therapy supply chain tracking and orchestration, announced the consortium comprising itself, the Cell and Gene Therapy (CGT) Catapult, Rexgenero and Fisher Bioservices (part of Thermo Fisher Scientific) has secured funding of £1.4 million from Innovate UK
Research & Development

New pluripotent stem cell media eliminates need for daily feeding

Allows two full-day breaks without changes to set up or protocol
Subscribe now